title: Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
abstract: The objective of this study was to compare the effectiveness of baclofen versus tizanidine as adjuvant treatment of botulinum toxin type A botulinum toxin type A in the management of children with spasticity. Thirty children with gastrocnemius spasticity were retrospectively reviewed at Gaziantep University Hospital, Gaziantep, Turkey. All patients were treated with localized botulinum toxin injections and baclofen or tizanidine for spasticity and were followed at 2- to 4-week intervals and evaluated for a total of 12 weeks; 17 children (57%) received baclofen and 13 (43%) received tizanidine. The mean score of Gross Motor Functional Measurement (76.63 +/- 5.88 vs 68.17 +/- 1.99; P < .001) and caregiver questionnaire scores (70.23 +/- 4.76 vs 66.59 +/- 3.53; P = .03) for the tizanidine group were significantly higher as compared with the baclofen group. This study suggests that combination of botulinum toxin type A with oral tizanidine is more effective with fewer side effects than combination of botulinum toxin type A and oral baclofen for spastic cerebral palsy.
authors.affiliation: Division of Pediatric Neurology, Department of Pediatrics, University of Gaziantep, Turkey.
authors.forename: Alper I
authors.initials: AI
authors.lastname: Dai
authors.forename: Mohammad
authors.initials: M
authors.lastname: Wasay
authors.forename: Safia
authors.initials: S
authors.lastname: Awan
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D001418:Baclofen / Q000008:administration & dosage*; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D002547:Cerebral Palsy / Q000150:complications / Q000188:drug therapy*; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D003000:Clonidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004359:Drug Therapy, Combination; D004863:Equinus Deformity / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009125:Muscle Relaxants, Central / Q000008:administration & dosage*; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D010865:Pilot Projects; D016896:Treatment Outcome
chemical_list: D009125:Muscle Relaxants, Central; D009465:Neuromuscular Agents; C023754:tizanidine; D019274:Botulinum Toxins, Type A; D001418:Baclofen; D003000:Clonidine